Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$23.53 -1.3%	$22.18	$13.40 ▼ $25.23	$3.99B	0.7	1.63 million shs	1.75 million shs
AMPH Amphastar Pharmaceuticals	$21.21 +1.2%	$23.71	$20.39 ▼ $53.96	$987.56M	0.76	454,819 shs	440,154 shs
PTCT PTC Therapeutics	$52.13 +0.0%	$49.21	$29.01 ▼ $58.38	$4.13B	0.54	1.12 million shs	1.02 million shs
SRRK Scholar Rock	$36.36 -1.9%	$35.27	$6.76 ▼ $46.98	$3.52B	0.48	1.15 million shs	1.42 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	-1.26%	+1.20%	+10.78%	+57.81%	+23.71%
AMPH Amphastar Pharmaceuticals	+1.24%	-5.19%	-10.05%	-13.43%	-51.26%
PTCT PTC Therapeutics	+0.04%	+16.52%	+6.06%	+4.36%	+54.00%
SRRK Scholar Rock	-1.86%	-6.65%	+2.28%	+10.48%	+300.44%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	4.0001 of 5 stars	3.4	3.0	0.0	2.5	4.2	2.5
AMPH Amphastar Pharmaceuticals	4.3834 of 5 stars	3.1	2.0	3.7	3.3	4.2	1.3
PTCT PTC Therapeutics	4.4836 of 5 stars	4.3	2.0	4.4	3.0	0.8	1.3
SRRK Scholar Rock	3.8089 of 5 stars	2.6	1.0	4.4	3.3	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.71	Moderate Buy	$28.13	19.53% Upside
AMPH Amphastar Pharmaceuticals	2.25	Hold	$32.33	52.44% Upside
PTCT PTC Therapeutics	2.67	Moderate Buy	$69.38	33.10% Upside
SRRK Scholar Rock	3.22	Buy	$44.14	21.40% Upside

Current Analyst Ratings Breakdown

Latest AMPH, SRRK, ACAD, and PTCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2025	SRRK Scholar Rock	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Strong-Buy	$53.00
7/29/2025	PTCT PTC Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$80.00 ➝ $86.00
7/29/2025	PTCT PTC Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$42.00 ➝ $46.00
7/29/2025	PTCT PTC Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$68.00 ➝ $84.00
7/29/2025	PTCT PTC Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$71.00 ➝ $80.00
7/29/2025	PTCT PTC Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$112.00 ➝ $120.00
7/29/2025	PTCT PTC Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$74.00 ➝ $78.00
7/28/2025	PTCT PTC Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$40.00 ➝ $50.00
7/24/2025	ACAD ACADIA Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$30.00 ➝ $34.00
7/17/2025	SRRK Scholar Rock	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
6/26/2025	ACAD ACADIA Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform	$19.00 ➝ $22.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$957.80M	4.11	$0.70 per share	33.81	$4.40 per share	5.35
AMPH Amphastar Pharmaceuticals	$731.97M	1.37	$5.06 per share	4.19	$15.23 per share	1.39
PTCT PTC Therapeutics	$806.78M	5.12	N/A	N/A	($14.24) per share	-3.66
SRRK Scholar Rock	$33.19M	104.02	N/A	N/A	$3.94 per share	9.23

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$226.45M	$1.37	17.18	30.96	6.63	22.97%	17.46%	10.75%	8/6/2025 (Estimated)
AMPH Amphastar Pharmaceuticals	$159.52M	$2.76	7.68	6.45	N/A	19.38%	22.20%	10.40%	8/7/2025 (Estimated)
PTCT PTC Therapeutics	-$363.30M	$6.51	8.01	N/A	N/A	33.56%	-78.56%	32.11%	8/7/2025 (Estimated)
SRRK Scholar Rock	-$246.29M	-$2.53	N/A	N/A	N/A	N/A	-118.22%	-82.01%	8/6/2025 (Estimated)

Latest AMPH, SRRK, ACAD, and PTCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	AMPH Amphastar Pharmaceuticals	$0.71	N/A	N/A	N/A	$173.42 million	N/A
8/7/2025	Q2 2025	PTCT PTC Therapeutics	-$1.07	N/A	N/A	N/A	$173.01 million	N/A
8/6/2025	Q2 2025	ACAD ACADIA Pharmaceuticals	$0.14	N/A	N/A	N/A	$263.07 million	N/A
8/6/2025	Q2 2025	SRRK Scholar Rock	-$0.68	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	SRRK Scholar Rock	-$0.63	-$0.67	-$0.04	-$0.67	N/A	N/A
5/7/2025	Q1 2025	ACAD ACADIA Pharmaceuticals	$0.10	$0.11	+$0.01	$0.11	$239.32 million	$244.32 million
5/6/2025	Q1 2025	PTCT PTC Therapeutics	$0.85	$10.04	+$9.19	N/A	$437.16 million	$1.18 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A
SRRK Scholar Rock	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.88	2.80
AMPH Amphastar Pharmaceuticals	0.80	2.95	2.02
PTCT PTC Therapeutics	N/A	3.89	3.85
SRRK Scholar Rock	0.16	10.25	10.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
AMPH Amphastar Pharmaceuticals	65.09%
PTCT PTC Therapeutics	N/A
SRRK Scholar Rock	91.08%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.50%
AMPH Amphastar Pharmaceuticals	27.50%
PTCT PTC Therapeutics	5.50%
SRRK Scholar Rock	13.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	167.36 million	123.01 million	Optionable
AMPH Amphastar Pharmaceuticals	2,028	47.14 million	34.18 million	Optionable
PTCT PTC Therapeutics	1,410	79.26 million	74.90 million	Optionable
SRRK Scholar Rock	140	94.95 million	82.32 million	Optionable

AMPH, SRRK, ACAD, and PTCT Headlines

Recent News About These Companies

TD Asset Management Inc Sells 23,794 Shares of Scholar Rock Holding Corporation (NASDAQ:SRRK)

August 1 at 7:10 AM | marketbeat.com

Scholar Rock (SRRK) Expected to Announce Earnings on Wednesday

July 31 at 10:48 AM | marketbeat.com

Scholar Rock (NASDAQ:SRRK) Now Covered by Raymond James Financial

July 31 at 9:35 AM | marketbeat.com

Victory Capital Management Inc. Buys 43,981 Shares of Scholar Rock Holding Corporation (NASDAQ:SRRK)

July 31 at 6:22 AM | marketbeat.com

Director Sells 11,136 Shares of SRRK, a Stock Up 330% in Past Year

July 24, 2025 | fool.com

Bank of New York Mellon Corp Has $6.95 Million Stake in Scholar Rock Holding Corporation (NASDAQ:SRRK)

July 24, 2025 | marketbeat.com

Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Sells 72,236 Shares of Scholar Rock Holding Corporation (NASDAQ:SRRK)

July 22, 2025 | marketbeat.com

Cantor Fitzgerald Forecasts Scholar Rock FY2025 Earnings

July 21, 2025 | marketbeat.com

Insider Selling: Scholar Rock Holding Corporation (NASDAQ:SRRK) Director Sells 11,136 Shares of Stock

July 19, 2025 | marketbeat.com

Jeffrey S. Flier Sells 11,136 Shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) Stock

July 19, 2025 | insidertrades.com

Cantor Fitzgerald Initiates Coverage of Scholar Rock Holding (SRRK) with Overweight Recommendation

July 18, 2025 | msn.com

Scholar Rock (NASDAQ:SRRK) Now Covered by Analysts at Cantor Fitzgerald

July 17, 2025 | marketbeat.com

Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Average Recommendation of "Buy" from Brokerages

July 16, 2025 | marketbeat.com

Scholar Rock Holding Corporation (NASDAQ:SRRK) Insider Sells $828,833.04 in Stock

July 10, 2025 | marketbeat.com

Scholar Rock (NASDAQ:SRRK) Trading 6.5% Higher - Should You Buy?

July 9, 2025 | marketbeat.com

Scholar Rock Holding Corporation (SRRK) - Yahoo Finance

July 4, 2025 | finance.yahoo.com

Scholar Rock Holding Corp. (SRRK) Stock Price Today - WSJ

June 24, 2025 | wsj.com

Scholar Rock Holding Corp News (SRRK) - Investing.com

June 24, 2025 | investing.com

Scholar Rock CEO on its drug that could preserve muscle in weight-loss drug users

June 24, 2025 | youtube.comY

Scholar Rock: EMBRAZE Results Drive The Stock Higher

June 23, 2025 | seekingalpha.com

Scholar Rock (SRRK) Jumps 16.6% After Successful Weight Loss Drug Trial

June 19, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMPH, SRRK, ACAD, and PTCT Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$23.53 -0.30 (-1.26%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$23.17 -0.36 (-1.53%)

As of 08/1/2025 07:12 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Amphastar Pharmaceuticals NASDAQ:AMPH

$21.21 +0.26 (+1.24%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$21.38 +0.18 (+0.83%)

As of 08/1/2025 04:20 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

PTC Therapeutics NASDAQ:PTCT

$52.13 +0.02 (+0.04%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$51.61 -0.52 (-1.01%)

As of 08/1/2025 06:51 PM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Scholar Rock NASDAQ:SRRK

$36.36 -0.69 (-1.86%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$36.36 +0.01 (+0.01%)

As of 08/1/2025 06:20 PM Eastern

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time